Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.
Women experience a decline in estrogen and androgen levels after natural or surgically induced menopause, effects that are associated with a loss of sexual desire and bone mineral density. Studies in our laboratories have shown the beneficial effects of selective androgen receptor modulators (SARMs) in the treatment of osteoporosis and muscle wasting in animal models. A series of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-trifluoromethyl-phenyl)-propionamide analogs was synthesized to evaluate the effects of B-ring substitutions on in vitro and in vivo pharmacologic activity, especially female sexual motivation. The androgen receptor (AR) relative binding affinities ranged from 0.1 to 26.5% (relative to dihydrotestosterone) and demonstrated a range of agonist activity at 100 nM. In vivo pharmacologic activity was first assessed by using male rats. Structural modifications to the B-ring significantly affected the selectivity of the SARMs, demonstrating that single-atom substitutions can dramatically and unexpectedly influence activity in androgenic (i.e., prostate) and anabolic (i.e., muscle) tissues. (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro,4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide (S-23) displayed full agonist activity in androgenic and anabolic tissues; however, the remaining SARMs were more prostate-sparing, selectively maintaining the size of the levator ani muscle in castrated rats. The partner-preference paradigm was used to evaluate the effects of SARMs on female sexual motivation. With the exception of two four-halo substituted analogs, the SARMs increased sexual motivation in ovariectomized rats, with potency and efficacy comparable with testosterone propionate. These results indicate that the AR is important in regulating female libido given the nonaromatizable nature of SARMs and it could be a superior alternative to steroidal testosterone preparations in the treatment of hypoactive sexual desire disorder.
Jones
Amanda
A
Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA.
Hwang
Dong Jin
DJ
Duke
Charles B
CB
He
Yali
Y
Siddam
Anjaiah
A
Miller
Duane D
DD
Dalton
James T
JT
D000728:Androgens; D000813:Anilides / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009919:Orchiectomy; D009929:Organ Size; D010052:Ovariectomy; D011467:Prostate / Q000033:anatomy & histology / Q000187:drug effects; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000502:physiology*; D012737:Sex Factors; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D015533:Transcriptional Activation; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects
D000728:Androgens; D000813:Anilides; C538983:N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methylpropanamide; D011944:Receptors, Androgen; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Bioorg Med Chem Lett. 2008 Jun 1;18(11):3431-5
18442912
Mol Pharmacol. 2003 Jan;63(1):211-23
12488554
Xenobiotica. 1996 Feb;26(2):117-22
8867996
J Pharmacol Exp Ther. 2005 Feb;312(2):546-53
15347734
Pharm Res. 2007 Feb;24(2):328-35
17063395
Endocrinology. 2005 Dec;146(12):5444-54
16166218
Bioorg Med Chem Lett. 2008 May 1;18(9):2967-71
18400499
Physiol Behav. 1983 Mar;30(3):437-43
6683412
Endocrinology. 2009 Jan;150(1):385-95
18772237
Horm Behav. 1989 Dec;23(4):473-502
2691387
Am J Obstet Gynecol. 1981 Aug 1;140(7):725-9
7196155
Gynecol Obstet Invest. 1992;34(2):97-101
1398273
J Pharmacol Exp Ther. 2005 Oct;315(1):230-9
15987833
J Clin Endocrinol Metab. 1974 Aug;39(2):340-6
4278727
J Med Chem. 2009 May 14;52(9):2794-8
19351168
J Pharmacol Exp Ther. 2003 Mar;304(3):1323-33
12604713
Endocrine. 2007 Aug;32(1):41-51
17992601
J Med Chem. 2004 Feb 12;47(4):993-8
14761201
Maturitas. 2008 Sep-Oct;61(1-2):17-26
19434876
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6
15833816
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5567-70
18805694
Psychosom Med. 1987 Jul-Aug;49(4):397-409
3615768
J Pharmacol Exp Ther. 2003 Mar;304(3):1334-40
12604714
Endocrinology. 2005 Nov;146(11):4887-97
16099859
Endocrinology. 2007 Jan;148(1):363-73
17023534
Menopause. 2006 Sep-Oct;13(5):770-9
16932240
Ann Intern Med. 2008 Apr 15;148(8):569-77
18413618
Fertil Steril. 2001 Sep;76(3):456-60
11532464
Eur J Med Chem. 2002 Aug;37(8):619-34
12161060
Horm Behav. 1998 Dec;34(3):283-93
9878277
J Clin Endocrinol Metab. 2005 Sep;90(9):5226-33
16014407
Medicine (Baltimore). 1992 Jan;71(1):44-51
1549058
Br J Pharmacol. 2008 May;154(2):440-50
18414397
Obstet Gynecol. 2005 May;105(5 Pt 1):944-52
15863529
Biochem Biophys Res Commun. 1998 Mar 6;244(1):1-4
9514878
Best Pract Res Clin Endocrinol Metab. 2002 Mar;16(1):31-41
11987896
J Med Chem. 2004 Jul 15;47(15):3765-76
15239655